Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045539 · ClinicalTrials.gov registry record · Phase 2
Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
A Phase 2 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00045539 is a Phase 2 study that has completed, run by New Approaches to Brain Tumor Therapy Consortium.
The verdict
NCT00045539, a Phase 2 study, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with thiotepa in treating patients who have newly-diagnosed primary CNS lymphoma.
Interventions
- DRUG leucovorin calcium
- DRUG methotrexate
- DRUG thiotepa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045539
The ClinicalTrials.gov registry entry for NCT00045539 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is New Approaches to Brain Tumor Therapy Consortium, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which leucovorin calcium is the first listed.
NCT00045539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045539 about?
NCT00045539 is a clinical study titled "Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma". RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with ...
What is the current status of trial NCT00045539?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00045539?
The interventions under investigation include: leucovorin calcium (DRUG), methotrexate (DRUG), thiotepa (DRUG).
Who is sponsoring clinical trial NCT00045539?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.